1. Home
  2. NTLA vs WLKP Comparison

NTLA vs WLKP Comparison

Compare NTLA & WLKP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • WLKP
  • Stock Information
  • Founded
  • NTLA 2014
  • WLKP 2014
  • Country
  • NTLA United States
  • WLKP United States
  • Employees
  • NTLA N/A
  • WLKP N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • WLKP Major Chemicals
  • Sector
  • NTLA Health Care
  • WLKP Industrials
  • Exchange
  • NTLA Nasdaq
  • WLKP Nasdaq
  • Market Cap
  • NTLA 710.1M
  • WLKP 833.7M
  • IPO Year
  • NTLA 2016
  • WLKP 2014
  • Fundamental
  • Price
  • NTLA $8.12
  • WLKP $23.07
  • Analyst Decision
  • NTLA Buy
  • WLKP
  • Analyst Count
  • NTLA 19
  • WLKP 0
  • Target Price
  • NTLA $38.26
  • WLKP N/A
  • AVG Volume (30 Days)
  • NTLA 3.2M
  • WLKP 24.4K
  • Earning Date
  • NTLA 05-08-2025
  • WLKP 05-02-2025
  • Dividend Yield
  • NTLA N/A
  • WLKP 8.17%
  • EPS Growth
  • NTLA N/A
  • WLKP N/A
  • EPS
  • NTLA N/A
  • WLKP 1.49
  • Revenue
  • NTLA $45,569,000.00
  • WLKP $1,088,852,000.00
  • Revenue This Year
  • NTLA N/A
  • WLKP $8.90
  • Revenue Next Year
  • NTLA N/A
  • WLKP $6.87
  • P/E Ratio
  • NTLA N/A
  • WLKP $15.48
  • Revenue Growth
  • NTLA N/A
  • WLKP N/A
  • 52 Week Low
  • NTLA $5.90
  • WLKP $21.19
  • 52 Week High
  • NTLA $28.18
  • WLKP $25.04
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 50.39
  • WLKP 47.02
  • Support Level
  • NTLA $7.21
  • WLKP $22.80
  • Resistance Level
  • NTLA $9.27
  • WLKP $23.42
  • Average True Range (ATR)
  • NTLA 0.61
  • WLKP 0.41
  • MACD
  • NTLA 0.02
  • WLKP -0.03
  • Stochastic Oscillator
  • NTLA 44.20
  • WLKP 38.52

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About WLKP Westlake Chemical Partners LP Common Units representing limited partner interests

Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.

Share on Social Networks: